ArticleChild's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2025
Effectiveness of vagus nerve stimulation in Dravet syndrome: a case series.
Article in Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this study is to report seizure outcomes for patients with Dravet syndrome (DS) who underwent vagus nerve stimulator (VNS) implantation at our center.
methodsWe conducted a retrospective review of patients with DS who underwent VNS implant at UPMC Children's Hospital of Pittsburgh from 2005 to 2024 with at least 1 year of follow-up. Demographics and medical history related to epilepsy were collected at baseline. The primary outcome was response to VNS at 1 and 2 years post-VNS, defined as ≥ 50% reduction in seizure frequency compared to baseline. The number of anti-seizure medications (ASMs) and diet modification were also collected at 1 and 2 years post-VNS.
resultsA total of 13 patients (69.2% female) with DS underwent VNS at a median age of 4.17 years (IQR, 2.58-4.58) and presented for follow-up at 1 (n = 13) and 2 (n = 9) years post-VNS. The response rate in our cohort was 61.5% (n = 8) at 1 year and 55.6% (n = 5) at 2 years post-VNS. Reduction in the number of ASMs was reported in a total of 7 (53.8%) patients, 4 of whom had reached the 2-year follow-up. Diet modification was attempted as a treatment strategy in 3 (23.1%) patients prior to VNS and maintained through 2 years post-VNS in 1 patient.
conclusionsVNS is associated with > 50% seizure frequency reduction in approximately 50% of patients with DS and may play a role in the multimodal treatment strategy employed for seizure control in these patients.
Indexed as
Identifiers
40580305What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.